keyword
MENU ▼
Read by QxMD icon Read
search

macroprolactinoma

keyword
https://www.readbyqxmd.com/read/28217516/long-term-cardiac-valvulopathy-safety-of-cabergoline-in-prolactinoma
#1
Shruti Khare, Anurag R Lila, Rishikesh Patil, Milind Phadke, Prafulla Kerkar, Tushar Bandgar, Nalini S Shah
BACKGROUND: Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear. OBJECTIVE: The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking cabergoline for the treatment of prolactinoma and to explore any associations with the cumulative dose of drug used. DESIGN: A cross-sectional echocardiographic study was performed in patients who were receiving cabergoline therapy for prolactinoma...
January 2017: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28209309/cluster-headache-and-macroprolactinoma-case-report-of-a-rare-but-potential-important-causality
#2
Lukas Andereggen, Marie-Luise Mono, Frauke Kellner-Weldon, Emanuel Christ
While headache is not an uncommon symptom in patients suffering from pituitary adenomas, cluster headache (CH) has rarely been reported in such cases. Headache associated with hyperprolactinemia has been reported to be responsive to dopamine agonists (DA agonists) in many patients. We report on a patient with refractory CH secondary to a macroprolactinoma who showed immediate and permanent clinical and radiologic recovery following medical treatment with DA agonists. Measurement of prolactin levels in addition to cranial magnetic resonance imaging might be considered in patients with refractory CH, until the significance of this potential causality becomes clearer...
February 10, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28096982/the-birth-and-rise-of-a-craniopharyngioma-the-radiological-evolution-of-an-incidental-craniopharyngioma-detected-on-serial-mri-during-medical-treatment-of-a-macroprolactinoma
#3
Stefano Mariotti, Marco Losa, Pietro Mortini, Luca Saba
This case demonstrates the rare coexistence of a prolactinoma with craniopharyngioma and documents its radiological growth. This case suggests that patients with pituitary neoplasms should be followed closely and although prolactinomas can often be managed medically, a coexistent other lesion may require surgery for histological assessment and to reduce mass effect.
January 2017: Clinical Case Reports
https://www.readbyqxmd.com/read/28073906/mri-follow-up-is-unnecessary-in-patients-with-macroprolactinomas-and-long-term-normal-prolactin-levels-on-dopamine-agonist-treatment
#4
MULTICENTER STUDY
J Eroukhmanoff, I Tejedor, I Potorac, T Cuny, J F Bonneville, H Dufour, G Weryha, A Beckers, P Touraine, T Brue, F Castinetti
OBJECTIVE: Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin is controlled. The aim of our study was to determine whether a regular MRI follow-up was necessary in patients with long-term normal prolactin levels under DA. PATIENTS AND METHODS: We conducted a retrospective multicenter study (Marseille, Paris La Pitie Salpetriere and Nancy, France; Liege, Belgium) including patients with macroprolactinomas (largest diameter: >10 mm and baseline prolactin level: >100 ng/mL) treated by dopamine agonists, and regularly followed (pituitary MRI and prolactin levels) during at least 48 months once normal prolactin level was obtained...
March 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/27926659/macroprolactinomas-and-nonfunctioning-pituitary-adenomas-and-pregnancy-outcomes
#5
Kimberley Lambert, Kate Rees, Paul T Seed, Mandish K Dhanjal, Marian Knight, David R McCance, Catherine Williamson
OBJECTIVE: To examine the monitoring, management, and outcomes of pituitary tumors in pregnancy. METHODS: A national, prospective, observational, population-based case series study was conducted in all U.K. consultant-led obstetric units over 3 years using the U.K. Obstetric Surveillance System. To evaluate rates of adverse pregnancy outcomes, women with a macroprolactinoma (10 mm or greater) or nonfunctioning pituitary adenoma, diagnosed before or during pregnancy, were compared with two comparison groups: 1) a U...
January 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/27908214/pregnancy-and-tumor-outcomes-in-infertile-women-with-macroprolactinoma-on-cabergoline-therapy
#6
Ashu Rastogi, Sanjay K Bhadada, Anil Bhansali
Hyperprolactinemia and prolactinomas cause infertility in significant number of women. But, pregnancy may lead to post-partum remission of hyperprolactinemia. The data on pregnancy and tumor outcome in women with macroprolactinoma conceiving on Cabergoline (CAB) therapy is increasing but still less than with Bromocriptine. We studied the incidence of fetal malformations, hyperprolactinemia and tumor course after gestation in infertile women harboring macroprolactinoma, who conceived on CAB therapy during the year 2005-2015...
December 2, 2016: Gynecological Endocrinology
https://www.readbyqxmd.com/read/27855233/a-macroprolactinoma-becoming-resistant-to-cabergoline-and-developing-atypical-pathology
#7
Emilia Sbardella, George Farah, Ahmed Fathelrahman, Simon Cudlip, Olaf Ansorge, Niki Karavitaki, Ashley B Grossman
Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and aggressive or nonaggressive. Prolactinomas account for 40-60% of all pituitary adenomas, with dopamine agonists representing the first-line treatment and surgery/radiotherapy reserved for drug intolerance/resistance or in neuro-ophthalmological emergencies. We present the case of a 62-year-old man with an apparently indolent prolactin-secreting macroadenoma managed with partial resection and initially showing a biochemical response to cabergoline...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27783196/management-of-prolactinomas-a-survey-of-physicians-from-the-middle-east-and-north-africa
#8
Salem A Beshyah, Ibrahim H Sherif, Farida Chentli, Amir Hamrahian, Aly B Khalil, Hussein Raef, Mohamed El-Fikki, Selim Jambart
BACKGROUND: Prolactinomas are the commonest functional tumors of the pituitary gland. There are still controversies regarding medical therapy in specific clinical situations. Patients may be managed by different specialists in the Middle East and North Africa (MENA) region and no data exist on patterns of clinical management. OBJECTIVES: To ascertain the diagnostic and therapeutic approaches to prolactinomas among relevant professionals from the MENA region. METHODS: An online survey of a large sample of physicians was conducted...
April 2017: Pituitary
https://www.readbyqxmd.com/read/27682355/surgical-outcomes-of-prolactinomas-in-recent-era-results-of-a-heterogenous-group
#9
Diane Donegan, John L D Atkinson, Mark Jentoft, Neena Natt, Tod B Nippoldt, Bradley Erickson, Fredric Meyer, Dana Erickson
OBJECTIVE: Prolactinomas are primarily treated with medical therapy. Given the efficacy of dopamine agonists (DAs), surgery has remained a second-line treatment option. Despite medical therapy, some tumors display resistance and/or patients maybe intolerant of DA and require alternative treatment options. We examined the indications, efficacy, and safety of pituitary surgery for the treatment of prolactinomas. METHODS: We performed a retrospective analysis of all patients who had surgery for a prolactinoma at our institution from January 1993 to October 2014...
January 2017: Endocrine Practice
https://www.readbyqxmd.com/read/27668187/approach-to-the-management-of-rare-clinical-presentations-of-macroprolactinomas-in-reproductive-aged-women
#10
Ana Espinosa De Ycaza, Alice Y Chang, Jani R Jensen, Zaraq Khan, Dana Erickson
OBJECTIVE: To describe 2 cases of macroprolactinomas with atypical presentation in women desiring pregnancy that illustrate important considerations in the management approach for macroprolactinomas in reproductive-aged women. PATIENTS: Case 1 was a 26-year-old woman referred to our institution for possible tumor resection after pituitary apoplexy during her first pregnancy. Instead, she underwent treatment with cabergoline for a year with goals of normalization of prolactin and decrease in tumor size to <1 cm before trying to conceive...
October 2015: Case Reports in Women's Health
https://www.readbyqxmd.com/read/27651307/long-term-results-of-cabergoline-therapy-for-macroprolactinomas-and-analyses-of-factors-associated-with-remission-after-withdrawal
#11
Shinya Watanabe, Hiroyoshi Akutsu, Shingo Takano, Tetsuya Yamamoto, Eiichi Ishikawa, Hiroaki Suzuki, Akira Matsumura
OBJECTIVE: Withdrawal of cabergoline is generally challenging, especially in patients with large or invasive macroprolactinomas. Therefore, we aimed to assess long-term results of cabergoline therapy for macroprolactinomas and remission achievement results after withdrawal in patients with macroprolactinomas. We also investigated clinical characteristics and factors related to remission after withdrawal. METHODS: This was an institutional review board-approved retrospective analysis...
February 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/27641080/long-term-outcome-of-macroprolactinomas
#12
MULTICENTER STUDY
Lori Képénékian, Hélène Cebula, Frédéric Castinetti, Thomas Graillon, Thierry Brue, Bernard Goichot
OBJECTIVE: Management of macroprolactinomas has dramatically changed in recent decades, from surgical to medical treatment as first-line therapy, with the development of dopamine agonists (DA). But few data exist on the long-term outcome of these patients. PATIENTS AND METHODS: Retrospective descriptive multicenter study of patients with macroprolactinoma followed for at least 5 years between 1973 and 2008 at the University Hospitals of Strasbourg and Marseille...
December 2016: Annales D'endocrinologie
https://www.readbyqxmd.com/read/27525431/treatment-of-hyperprolactinaemia-reduces-total-cholesterol-and-ldl-in-patients-with-prolactinomas
#13
Verena Schwetz, Rosaria Librizzi, Christian Trummer, Georg Theiler, Claudia Stiegler, Thomas R Pieber, Barbara Obermayer-Pietsch, Stefan Pilz
Previous studies suggest that hyperprolactinaemia might have adverse effects on lipid and glucose metabolism. We therefore aimed to evaluate whether dopamine agonist treatment with cabergoline has significant effects on blood lipids, fasting glucose and HbA1c levels in patients with micro- or macroprolactinoma. In this retrospective observational study the main outcome measures are changes in parameters of glucose and lipid metabolism compared at hyperprolactinaemia and after achievement of normoprolactinaemia by cabergoline treatment...
August 15, 2016: Metabolic Brain Disease
https://www.readbyqxmd.com/read/27487374/prolactinomas-may-have-unusual-presentations-resulting-from-massive-extrasellar-tumor-extension
#14
Marise Ribeiro de Sousa Berriel, Giovanna Aparecida Balarini Lima, Alessandro Severo Alves de Melo, Maria Laura Vasconcelos Dos Santos, Hassan Rahhal, Giselle Fernandes Taboada
The purpose of this case series is to report eight patients with giant prolactinomas emphasizing presentations and a treatment complication. The study group included six men and two women. The median age was 29 years (18-54 years); median serum prolactin level was 4,562 ng/ml (1,543-18,690 ng/ml); three patients (37.5%) had panhypopituitarism; median tumor diameter was 50 mm (41-60 mm). Five patients (62.5%) had visual field defects and three had improvement during treatment; six patients (75%) reached prolactin normalization, with a median time of 10...
July 2016: Arquivos de Neuro-psiquiatria
https://www.readbyqxmd.com/read/27460005/dopamine-agonist-therapy-induces-significant-recovery-of-hpa-axis-function-in-prolactinomas-independent-of-tumor-size-a-large-single-center-experience
#15
Christine G Yedinak, Isabelle Cetas, Alp Ozpinar, Shirley McCartney, Aclan Dogan, Maria Fleseriu
Our objective was to compare prevalence and rates of recovery of hypothalamic-pituitary-adrenal axis dysfunction in prolactinoma patients before and after dopamine agonist therapy with nonfunctioning pituitary adenoma patients pre-transsphenoidal and post-transsphenoidal surgery. We retrospectively compared hypothalamic-pituitary-adrenal axis function in patients with prolactinomas naïve to dopamine agonist therapy with a cohort of nonfunctioning pituitary adenoma patients matched for gender and tumor size by classification (n = 57; 30 male/27 female; 27 microadenoma/30 macroadenoma)...
October 2016: Endocrine
https://www.readbyqxmd.com/read/27400437/topiramate-overcoming-dopamine-agonist-induced-migraine-exacerbation-and-avoiding-transsphenoidal-surgery-in-a-young-boy-with-a-macroprolactinoma
#16
LETTER
André M Faria, Paula de F Presti, Durval Damiani, Nina Rosa Musolino, Malebranche B C Cunha Neto
No abstract text is available yet for this article.
October 2016: Headache
https://www.readbyqxmd.com/read/27400138/ventriculitis-from-a-pituitary-prolactinoma-bacterial-or-chemical
#17
Bodiabaduge A P Jayasekera, Julie Hall, Simon Pearce, Alistair J Jenkins
We report the case of a 70-year-old man presenting with pituitary apoplexy from a macroprolactinoma and ventriculitis. It was not possible to distinguish a bacterial or chemical origin, on the basis of his clinical presentation, laboratory studies and imaging, highlighting the importance of prompt imaging and attainment of CSF cultures, in making the diagnosis.
April 2017: British Journal of Neurosurgery
https://www.readbyqxmd.com/read/27130071/prolactinoma-and-pregnancy-from-the-wish-of-conception-to-lactation
#18
REVIEW
Dominique Maiter
Prolactinoma is a common cause of infertility in young women and treatment with dopamine agonists (DA) allows restoration of fertility in over 90% of the cases. Both bromocriptine and cabergoline have shown a good safety profile when administered during early pregnancy. In particular, data on exposure of the fetus or embryo to cabergoline during the first weeks of pregnancy have now been reported in more than 900 cases, and do indicate that cabergoline is safe in this context. There is no increase in the frequency of spontaneous miscarriage, premature delivery, multiple births or neonatal malformations, and follow-up studies of the children for up to 12years after fetal exposure to cabergoline did not show any physical or developmental abnormalities...
June 2016: Annales D'endocrinologie
https://www.readbyqxmd.com/read/26909481/prolactinomas-evolution-after-menopause
#19
MULTICENTER STUDY
Maria Susana Mallea-Gil, Marcos Manavela, Analia Alfieri, Maria Carolina Ballarino, Alberto Chervin, Karina Danilowicz, Sabrina Diez, Patricia Fainstein Day, Natalia García-Basavilbaso, Mariela Glerean, Mirtha Guitelman, Débora Katz, Monica Graciela Loto, Marcela Martinez, Karina Miragaya, Daniel Moncet, Amelia Susana Rogozinski, Marisa Servidio, Graciela Stalldecker
OBJETIVE: The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. SUBJECTS AND METHODS: Retrospective study, 29 patients with prolactinomas, 22 microadenomas and 7 macroadenomas, diagnosed during their fertile age were studied in their menopause; treatment was stopped in this period...
February 2016: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/26830552/withdrawal-of-dopamine-agonist-therapy-in-prolactinomas-in-which-patients-and-when
#20
Sema Ciftci Dogansen, Ozlem Soyluk Selcukbiricik, Seher Tanrikulu, Sema Yarman
PURPOSE: The aim of the study was to assess the effect of dopamine agonist (DA) withdrawal, the current recurrence rate of hyperprolactinemia, and possible factors that predict recurrence in patients with prolactinoma. METHODS: We evaluated DA withdrawal in 67 patients with prolactinoma (50 female/17 male) who received DA treatment for at least 2 years and showed normalization of prolactin (PRL) levels and tumor disappearance or ≥50 % tumor shrinkage, retrospectively...
June 2016: Pituitary
keyword
keyword
59456
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"